갑상선질환에서 골건강 평가 및 관리 권고안

키워드

참고문헌 (112)

1. Wexler JA, "Thyroid and bone", Endocrinol Metab Clin North Am, 36(3), pp.673~705 (2007)
2. Mundy GR, "Direct stimulation of bone resorption by thyroid hormones", J Clin Invest, 58(3), pp.529~534 (1976)
3. Kanatani M, "Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction", J Cell Physiol, 201(1), pp.17~25 (2004)
4. Bassett JH, "Role of thyroid hormones in skeletal development and bone maintenance", Endocr Rev, 37(2), pp.135~187 (2016)
5. Vestergaard P, "Fractures in patients with hyperthyroidism and hypothyroidism : a nationwide follow-up study in 16, 249 patients", Thyroid, 12(5), pp.411~419 (2002)
6. Abrahamsen B, "The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time : an observational register-based time-resolved cohort analysis", J Bone Miner Res, 30(5), pp.898~905 (2015)
7. 고영진, "Levothyroxine Dose and Fracture Risk According to the Osteoporosis Status in Elderly Women", 예방의학회지, 47(1), pp.36~46 (2014), 대한예방의학회
8. Uzzan B, "Effects on bone mass of long term treatment with thyroid hormones : a meta-analysis", J Clin Endocrinol Metab, 81(12), pp.4278~4289 (1996)
9. Ross DS, "Hyperthyroidism, thyroid hormone therapy, and bone", Thyroid, 4(3), pp.319~326 (1994)
10. Heemstra KA, "The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma", Thyroid, 16(6), pp.583~591 (2006)
11. Cellini M, "Skeletal health in patients with differentiated thyroid carcinoma", J Endocrinol Invest, 44(3), pp.431~442 (2021)
12. Notsu M, "Papillary thyroid carcinoma is a risk factor for severe osteoporosis", J Bone Miner Metab, 38(2), pp.264~270 (2020)
13. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
14. 문재훈, "The Diagnosis and Management of Hyperthyroidism in Korea: Consensus Report of the Korean Thyroid Association", Endocrinology and Metabolism, 28(4), pp.275~279 (2013), 대한내분비학회
15. Ross DS, "2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis", Thyroid, 26(10), pp.1343~1421 (2016)
16. Carle A, "Management of endocrine disease : subclinical thyrotoxicosis : prevalence, causes and choice of therapy", Eur J Endocrinol, 176(6), pp.R325~R37 (2017)
17. 진상욱, "Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement", Endocrinology and Metabolism, 34(1), pp.53~62 (2019), 대한내분비학회[DOI]
18. 김경진, "Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force", Endocrinology and Metabolism, 36(2), pp.322~338 (2021), 대한내분비학회[DOI]
19. Mosekilde L, "Effects of thyroid hormones on bone and mineral metabolism", Endocrinol Metab Clin North Am, 19(1), pp.35~63 (1990)
20. Mosekilde L, "Bone changes in hyperthyroidism:interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism", Acta Endocrinol(Copenh), 85(3), pp.515~525 (1977)
21. Bours SP, "Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture", J Clin Endocrinol Metab, 96(5), pp.1360~1367 (2011)
22. Garnero P, "Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women : the OFELY study", J Bone Miner Res, 15(8), pp.1526~1536 (2000)
23. Bauer DC, "Risk for fracture in women with low serum levels of thyroid-stimulating hormone", Ann Intern Med, 134(7), pp.561~568 (2001)
24. Vestergaard P, "Influence of hyperand hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk", Calcif Tissue Int, 77(3), pp.139~144 (2005)
25. Cummings SR, "Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group", N Engl J Med, 332(12), pp.767~773 (1995)
26. Wejda B, "Hip fractures and the thyroid : a case-control study", J Intern Med, 237(3), pp.241~247 (1995)
27. Vestergaard P, "Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis", Thyroid, 13(6), pp.585~593 (2003)
28. Dhanwal DK, "Bone mineral density trends in Indian patients with hyperthyroidism--effect of antithyroid therapy", J Assoc Physicians India, 59, pp.561~562 (2011)
29. Marshall D, "Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures", BMJ, 312(7041), pp.1254~1259 (1996)
30. Torgerson DJ, "Prediction of perimenopausal fractures by bone mineral density and other risk factors", J Bone Miner Res, 11(2), pp.293~297 (1996)
31. Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update, 2020, pp.26(Suppl 1), 1~46
32. Shoback D, "Pharmacological management of osteoporosis in postmenopausal women : an Endocrine Society guideline update", J Clin Endocrinol Metab, 105(3), pp.dgaa048~ (2020)
33. "Physician's guideline for osteoporosis", The Korean Society of Bone and Mineral Research, ~ (2020)
34. Udayakumar N, "Evaluation of bone mineral density in thyrotoxicosis", Singapore Med J, 47(11), pp.947~950 (2006)
35. Ale AO, "Prevalence, predictive factors, and characteristics of osteoporosis in hyperthyroid patients", Int J Endocrinol, 2018, pp.3540256~ (2018)
36. Kuzma M, "High serum fractalkine is associated with lower trabecular bone score in premenopausal women with Graves' disease", Horm Metab Res, 50(8), pp.609~614 (2018)
37. Boonya-Ussadorn T, "A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women", J Med Assoc Thai (2010)
38. Garnero P, "Markers of bone turnover in hyperthyroidism and the effects of treatment", J Clin Endocrinol Metab, 78(4), pp.955~959 (1994)
39. Harvey RD, "Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers", J Clin Endocrinol Metab, 72(6), pp.1189~1194 (1991)
40. Kisakol G, "Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism", Endocr J, 50(6), pp.657~661 (2003)
41. Sabuncu T, "Early changes in parameters of bone and mineral metabolism during therapy for hyper-and hypothyroidism", Endocr Res, 27(1-2), pp.203~213 (2001)
42. Olkawa M, "Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time", Clin Endocrinol(Oxf), 50(2), pp.171~176 (1999)
43. Karunakaran P, "Rapid restoration of bone mass after surgical management of hyperthyroidism : a prospective case control study in Southern India", Surgery, 159(3), pp.771~776 (2016)
44. Kumeda Y, "Persistent increase in bone turnover in Graves'patients with subclinical hyperthyroidism", J Clin Endocrinol Metab, 85(11), pp.4157~4161 (2000)
45. Zhong N, "Positive correlation between serum osteocalcin and testosterone in male hyperthyroidism patients with high bone turnover", Exp Clin Endocrinol Diabetes, 124(7), pp.452~456 (2016)
46. 옥소영, "Changes in bone mineral density and trabecular bone score in Graves’ disease patients after anti-thyroid therapy", Osteoporosis and Sarcopenia, 2(3), pp.175~179 (2016), 대한골다공증학회[DOI]
47. Nicolaisen P, "Consequences of hyperthyroidism and its treatment for bone microarchitecture assessed by high-resolution peripheral quantitative computed tomography", Thyroid, 31(2), pp.208~216 (2021)
48. Kim KM, "Interactions between dietary calcium intake and bone mineral density or bone geometry in a low calcium intake population(KNHANES IV 2008-2010)", J Clin Endocrinol Metab, 99(7), pp.2409~2417 (2014)
49. Park JH, "Vitamin D status in South Korean population: seven-year trend from the KNHANES", Medicine(Baltimore), 97(26), pp.e11032~ (2018)
50. Lupoli G, "Effects of alendronate on bone loss in pre-and postmenopausal hyperthyroid women treated with methimazole", Gynecol Endocrinol, 10(5), pp.343~348 (1996)
51. Lupoli GA, "Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients", Minerva Endocrinol, 30(2), pp.89~94 (2005)
52. Majima T, "Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease", J Bone Miner Metab, 24(2), pp.105~113 (2006)
53. Kanis JA, "Interpretation and use of FRAX in clinical practice", Osteoporos Int, 22(9), pp.2395~2411 (2011)
54. Cooper DS, "Subclinical thyroid disease", Lancet, 379(9821), pp.1142~1154 (2012)
55. Amato G, "High serum osteoprotegerin levels in patients with hyperthyroidism : effect of medical treatment", Bone, 35(3), pp.785~791 (2004)
56. Gürlek A, "Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women", Thyroid, 9(6), pp.539~543 (1999)
57. Tauchmanovà L, "Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in preand postmenopausal women with endogenous subclinical hyperthyroidism", Maturitas, 48(3), pp.299~306 (2004)
58. Lee WY, "Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women", Arch Med Res, 37(4), pp.511~516 (2006)
59. Wartofsky L, "Subclinical hyperthyroidism and fracture risk in women", J Clin Endocrinol Metab, 99(8), pp.2654~2656 (2014)
60. Földes J, "Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?", Clin Endocrinol (Oxf), 39(5), pp.521~527 (1993)
61. Faber J, "Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism:effect on bone loss in postmenopausal women", Clin Endocrinol (Oxf), 48(3), pp.285~290 (1998)
62. Yan Z, "Relationship between subclinical thyroid dysfunction and the risk of fracture : a meta-analysis of prospective cohort studies", Osteoporos Int, 27(1), pp.115~125 (2016)
63. Saler T, "Endogenous subclinical hyperthyroidism may not lead to bone loss in premenopausal women", Hippokratia, 18(3), pp.240~244 (2014)
64. Nicholls JJ, "The skeletal consequences of thyrotoxicosis", J Endocrinol, 213(3), pp.209~221 (2012)
65. Lee JS, "Subclinical thyroid dysfunction and incident hip fracture in older adults", Arch Intern Med, 170(21), pp.1876~1883 (2010)
66. Blum MR, "Subclinical thyroid dysfunction and fracture risk : a meta-analysis", JAMA, 313(20), pp.2055~2065 (2015)
67. Wirth CD, "Subclinical thyroid dysfunction and the risk for fractures : a systematic review and meta-analysis", Ann Intern Med, 161(3), pp.189~199 (2014)
68. Kung AW, "Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women : the effect of calcium and calcitonin", J Clin Endocrinol Metab, 81(3), pp.1232~1236 (1996)
69. Grant AM, "Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people(Randomised Evaluation of Calcium Or vitamin D, RECORD) : a randomised placebo-controlled trial", Lancet, 365(9471), pp.1621~1628 (2005)
70. Tang BM, "Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older : a meta-analysis", Lancet, 370(9588), pp.657~666 (2007)
71. Weaver CM, "Vitamin D requirements : current and future", Am J Clin Nutr, 80(6 Suppl), pp.1735S~1739S (2004)
72. Avenell A, "Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis", Cochrane Database Syst Rev, (2), pp.CD000227~ (2009)
73. Schneider DL, "Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen", JAMA, 271(16), pp.1245~1249 (1994)
74. Rosen HN, "Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans", J Clin Endocrinol Metab, 77(3), pp.664~669 (1993)
75. Faber J, "Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment : a meta-analysis", Eur J Endocrinol, 130(4), pp.350~356 (1994)
76. Papaleontiou M, "Effect of thyrotropin suppression therapy on bone in thyroid cancer patients", Oncologist, 21(2), pp.165~171 (2016)
77. 윤병호, "Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis", 대한골대사학회지, 26(1), pp.51~60 (2019), 대한골대사학회
78. Wang MY, "TSHsuppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma : a meta-analysis", Eur Rev Med Pharmacol Sci, 24(2), pp.922~929 (2020)
79. Ku EJ, "Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer : a systematic review and meta-analysis", J Clin Endocrinol Metab, 106(12), pp.3655~3667 (2021)
80. Kwak D, "Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women : a systematic review and meta-analysis", BMJ Open, 11(5), pp.e043007~ (2021)
81. Fujiyama K, "Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women", Thyroid, 5(1), pp.13~17 (1995)
82. Heijckmann AC, "Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma", Eur J Endocrinol, 153(1), pp.23~29 (2005)
83. Reverter JL, "Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma", Endocrine, 37(3), pp.467~472 (2010)
84. Vera L, "Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy", Endokrynol Pol, 67(4), pp.350~358 (2016)
85. Mazziotti G, "High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma", J Clin Endocrinol Metab, 103(3), pp.956~964 (2018)
86. Lin SY, "Risk of osteoporosis in thyroid cancer patients using levothyroxine : a populationbased study", Curr Med Res Opin, 34(5), pp.805~812 (2018)
87. Shin DW, "J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients : a retrospective cohort study", J Bone Miner Res, 33(6), pp.1037~1043 (2018)
88. Bin-Hong D, "Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy", Endokrynol Pol, 71(1), pp.15~20 (2020)
89. 이미영, "Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer", Annals of Surgical Treatment and Research, 86(2), pp.55~60 (2014), 대한외과학회
90. Moon JH, "The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 102(1), pp.78~85 (2017)
91. De Mingo Dominguez ML, "Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy", Endocrine, 62(1), pp.166~173 (2018)
92. Hawkins Carranza F, "Trabecular bone deterioration in differentiated thyroid cancer : impact of long-term TSH suppressive therapy", Cancer Med, 9(16), pp.5746~5755 (2020)
93. Moon JH, "The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma", Bone, 83, pp.104~110 (2016)
94. Tournis S, "Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression", Clin Endocrinol(Oxf), 82(2), pp.197~204 (2015)
95. Kim K, "Evaluation of bone mineral density using DXA and cQCT in postmenopausal patients under thyrotropin suppressive therapy", J Clin Endocrinol Metab, 103(11), pp.4232~4240 (2018)
96. Panico A, "Osteoporosis and thyrotropin-suppressive therapy : reduced effectiveness of alendronate", Thyroid, 19(5), pp.437~442 (2009)
97. Panebianco P, "Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy", Arch Gerontol Geriatr, 25(2), pp.219~225 (1997)
98. Asari R, "Hypoparathyroidism after total thyroidectomy : a prospective study", Arch Surg, 143(2), pp.132~137 (2008)
99. Pattou F, "Hypocalcemia following thyroid surgery : incidence and prediction of outcome", World J Surg, 22(7), pp.718~724 (1998)
100. Roher HD, "Complications in thyroid surgery. Incidence and therapy", Chirurg, 70(9), pp.999~1010 (1999)
101. Thomusch O, "The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery : a multivariate analysis of 5846 consecutive patients", Surgery, 133(2), pp.180~185 (2003)
102. Thomusch O, "Multivariate analysis of risk factors for postoperative complications in benign goiter surgery : prospective multicenter study in Germany", World J Surg, 24(11), pp.1335~1341 (2000)
103. Testini M, "Hypoparathyroidism after total thyroidectomy", Minerva Chir, 62(5), pp.409~415 (2007)
104. Kakava K, "Postsurgical hypoparathyroidism : a systematic review", In Vivo, 30(3), pp.171~179 (2016)
105. Silva B, "The parathyroids", pp.127~137 (2015), Elsevier Inc
106. Rubin MR, "Dynamic and structural properties of the skeleton in hypoparathyroidism", J Bone Miner Res, 23(12), pp.2018~2024 (2008)
107. Clarke BL, "Bone disease in hypoparathyroidism", Arq Bras Endocrinol Metabol, 58(5), pp.545~552 (2014)
108. Chan FK, "Increased bone mineral density in patients with chronic hypoparathyroidism", J Clin Endocrinol Metab, 88(7), pp.3155~3159 (2003)
109. Amrein K, "Low bone turnover and increase of bone mineral density in a premenopausal woman with postoperative hypoparathyroidism and thyroxine suppressive therapy", Osteoporos Int, 22(11), pp.2903~2905 (2011)
110. Takamura Y, "Attenuation of postmenopausal bone loss in patients with transient hypoparathyroidism after total thyroidectomy", World J Surg, 37(12), pp.2860~2865 (2013)
111. Bollerslev J, "European Society of Endocrinology Clinical Guideline : treatment of chronic hypoparathyroidism in adults", Eur J Endocrinol, 173(2), pp.G1~20 (2015)
112. Orloff LA, "American Thyroid Association statement on postoperative hypoparathyroidism : diagnosis, prevention, and management in adults", Thyroid, 28(7), pp.830~841 (2018)

관련 논문AI추천